ArticleFunctional & integrative genomics2026
Cross-phenotype and cross-species integrative genomic prioritization of FOXF2 and FOXC1 at a cerebral small vessel disease locus.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cerebral small vessel disease (CSVD) is genetically heterogeneous, and translating regional association signals into biologically plausible effector-gene hypotheses remains challenging. We performed a cross-phenotype and cross-species integrative genomic analysis of the FOXF2-centered proximal chromosome 6 region using publicly available genome-wide association study summary statistics for lacunar stroke, small-vessel disease ischemic stroke subtype and white matter hyperintensity volume. The chr6:0-2.5 Mb interval was treated as the primary regional analysis, whereas FOXF2 ± 1 Mb and FOXF2 ± 500 kb were examined as nested sensitivity windows. Linkage disequilibrium, regional gene annotation, quantitative trait locus evidence, colocalization, fine-mapping, GWAS Catalog records and human and mouse brain vascular transcriptomic data were integrated within a predefined candidate-prioritization framework. Lacunar stroke showed the strongest regional evidence, with rs7766042 meeting the predefined broad-window local correction threshold, although no signal reached conventional genome-wide significance. The SVD ischemic stroke subtype and WMH signals did not meet their corresponding local correction thresholds. Phenotype-specific lead variants showed low pairwise linkage disequilibrium, a pattern consistent with regional signal heterogeneity but not sufficient to establish distinct causal signals. FOXF2 and FOXC1 were prioritized as leading neurovascular candidates, whereas EXOC2 and GMDS were retained as secondary positional candidates. Several regional variants overlapped FOXF2 eQTL annotations; however, formal colocalization showed little evidence for a shared causal variant (PP.H4 = 0.0604), and fine-mapping did not resolve a single causal variant. Human and mouse brain vascular transcriptomic analyses provided cross-species expression-based cellular context for FOXF2 and FOXC1. These findings support regional candidate-gene prioritization at the proximal chromosome 6 locus while emphasizing that the available evidence does not establish a definitive multi-signal or multi-gene causal architecture.
Indexed as
Identifiers
42832086What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.